Literature DB >> 1281759

Glucocorticoids in clinical oncology.

D Walsh1, J Avashia.   

Abstract

Glucocorticoids have been used in clinical oncology for more than three decades. Their anti-inflammatory action plays a major role in their clinical applications in oncology. The incidence and severity of side effects depend on the total dose and the duration of therapy, but optimal dosages for these drugs have not been determined. Little is known about other risk factors for toxicity. Prednisone and dexamethasone, the two most commonly used drugs, are well absorbed orally and share quantitatively similar pharmacokinetic values. No definite relationship is known between the glucocorticoid blood level (total and unbound concentration) and therapeutic effect. Glucocorticoids play a major role in the treatment of lymphoproliferative disorders and breast cancer, and they often succeed in palliating common symptoms in advanced cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281759     DOI: 10.3949/ccjm.59.5.505

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  16 in total

1.  Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study.

Authors:  Marilyn L Kwan; Jeanne Darbinian; Kathryn H Schmitz; Rebecca Citron; Paula Partee; Susan E Kutner; Lawrence H Kushi
Journal:  Arch Surg       Date:  2010-11

2.  Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of ZO-1 tight junction protein.

Authors:  Christopher D Hue; Frances S Cho; Siqi Cao; Cameron R Dale Bass; David F Meaney; Barclay Morrison
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-11       Impact factor: 6.200

3.  Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.

Authors:  Lindsay K Smith; John A Cidlowski
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

4.  Metabolic effects of prazosin on skeletal muscle insulin resistance in glucocorticoid-treated male rats.

Authors:  Emily C Dunford; Erin R Mandel; Sepideh Mohajeri; Tara L Haas; Michael C Riddell
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-11-09       Impact factor: 3.619

Review 5.  Modern management of the cancer anorexia-cachexia syndrome.

Authors:  K A Nelson
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

6.  Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial.

Authors:  Daniel J Zheng; Xiaomin Lu; Reuven J Schore; Lyn Balsamo; Meenakshi Devidas; Naomi J Winick; Elizabeth A Raetz; Mignon L Loh; William L Carroll; Lillian Sung; Stephen P Hunger; Anne L Angiolillo; Nina S Kadan-Lottick
Journal:  Cancer       Date:  2017-11-07       Impact factor: 6.860

Review 7.  The risks and benefits of corticosteroids in advanced cancer.

Authors:  R Twycross
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

8.  Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.

Authors:  Anne L Angiolillo; Reuven J Schore; John A Kairalla; Meenakshi Devidas; Karen R Rabin; Patrick Zweidler-McKay; Michael J Borowitz; Brent Wood; Andrew J Carroll; Nyla A Heerema; Mary V Relling; Johann Hitzler; Ashley R Lane; Kelly W Maloney; Cindy Wang; Mylène Bassal; William L Carroll; Naomi J Winick; Elizabeth A Raetz; Mignon L Loh; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2021-01-07       Impact factor: 44.544

Review 9.  Modern management of the cancer anorexia-cachexia syndrome.

Authors:  K A Nelson
Journal:  Curr Pain Headache Rep       Date:  2001-06

10.  A transition in transcriptional activation by the glucocorticoid and retinoic acid receptors at the tumor stage of dermal fibrosarcoma development.

Authors:  M D Vivanco; R Johnson; P E Galante; D Hanahan; K R Yamamoto
Journal:  EMBO J       Date:  1995-05-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.